Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey

World Journal of Gastroenterology

Volumn 10, Issue 5, 2004, Pages 668-671

  Gumurdulu, Yuksel ^a   Serin, Ender ^a   Özer, Birol ^a   Kayaselcuk, Fazilet ^a   Ozsahin, Kursat ^a   Cosar, Arif Mansur ^a   Gursoy, Murat ^a   Gur, Gurden ^a   Yilmaz, Ugur ^a   Boyacioglu, Sedat ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE; TETRACYCLINE;

ADOLESCENT; ADULT; AGE; AGED; ANAMNESIS; ARTICLE; BACTERIUM DETECTION; CIGARETTE SMOKING; CONTROLLED STUDY; CORRELATION FUNCTION; DENSITY; DUODENUM ULCER; ERADICATION THERAPY; FEMALE; GASTRITIS; GASTROINTESTINAL BIOPSY; GENDER; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; NONHUMAN; PREDICTION; SCORING SYSTEM; STATISTICAL ANALYSIS; STOMACH ANTRUM; STOMACH ULCER; TREATMENT FAILURE; TURKEY (REPUBLIC);

EID: 12144289669     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i5.668     Document Type: Article

References (35)

1. Ikeda S, Tamamuro T, Hamashima C, Asaka M. Evaluation of the cost-effectiveness of Helicobacter pylori eradication triple therapy vs conventional therapy for ulcers in Japan. Aliment Pharmacol Ther 2001; 15: 1777-1785
2. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-180
3. Marzio L, Cellini L, Angelucci D. Triple therapy for 7 days vs. triple therapy for 7 days plus omeprazole for 21 days in treatment of active duodenal ulcer with Helicobacter pylori infection. A double blind placebo controlled trial. Dig Liver Dis 2003; 35: 20-23
4. Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001; 15: 1949-1958
5. Tytgat GN. Review article: Treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther 1994; 8: 359-368
6. Bhasin DK, Sharma BC, Ray P, Pathak CM, Singh K. Comparison of Seven and Fourteen Days of Lansaprazole, Claritromycin and amoxicillin Therapy for Eradication of Helicobacter pylori:A Report from India. Helicobacter 2000; 5: 84-87
7. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and Grading of Gastritis. The Updated Sydney system. Am J Surg Pathol 1996; 20: 1161-1181
8. Yang HB, Sheu BS, Su IJ, Chien CH, Lin XZ. Clinical Application of Gastric Histology to Monitor Treatment of Dual Therapy in H pylori Eradication. Dig Dis Sci 1997; 42: 1835-1840
9. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; 1: 1273-1275
10. World Health Organization. International agency for research on cancer. Ýnfection with Helicobacter pylori. Schistosomes, Liver flukes and Helicobacter pylori. Lyon: IARC 1994: 172-202
11. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: A review. Gastroenterology 1996; 110: 1244-1252
12. Peitz U, Hackelsberger A, Malfertheiner P. A practical approach to patients with refractory Helicobacter pylori infection,or who are re-infected after standart therapy. Drugs 1999; 57: 905-920
13. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 16: 1311-1315
14. Working Party of the european Helicobacter pylori study group. Guidelines for clinical trials in Helicobacter pylori infection. Gut 1997; 41(Suppl 2): S1-9
15. Soll AH. Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology. JAMA 1996; 275: 622-628
16. Taskin V, Özyilkan E, Aydin A, Çetin F, Eskiolu E, Köseoolu T. Can resistant Helicobacter pylori infection be estimated histologically: Effects of gastric histology on eradication rates of Helicobacter pylori infection. The Turk J Gastroenterol 2001; 12: 126-129
17. Aydin A, Ersöz G, Tunçyürek M, Cavusoglu H. One-week triple therapies for Helicobacter pylori eradication. The Turk J Gastroenterol 1998; 9: 40-45
18. Iwahi T, Satoh H, Nakao M, Iwasaki T, Yamazaki T, Kubo K, Tamura T, Imada A. Lansaprazole,a novel benzimidazole proton pump inhibitor,and its related compounds have selective activity aganist Helicobacter pylori. Antim Agents Chem 1991; 35: 490-496
19. Hunt RH. pH and H pylori-gastric acid secretion and Helicobacter pylori. Ýmplications for ulcer healing and eradication the organism. Am J Gastroenterol 1993; 88: 481-483
20. Glupczynski Y. Antimicrobial resistance in Helicobacter pylori: A global overview. Acta Gastroenterol Belg 1998; 61: 357-366
21. Georgopoulos SD, Ladas SD, Karatapanis S, Mentis A, Spiliadi C, Artikis V, Raptis SA. Factors that may Affect Treatment Outcome of Triple Helicobacter pylori Eradication Therapy with Omeprazole,Amoxicillin,and Clarithromycin. Dig Dis Sci 2000; 45: 63-67
22. Huang JQ, Hunt RH. Treatment after failure:tHe problem of "nOn-responders". Gut 1999; 45(Suppl1): 140-144
23. Kim JJ, Reddy R, Lee M, Kim JG, El-Zaatari FA, Osato MS, Graham DY, Kwon DH. Analysis of metronidazole, claritromycin and tetracycline resistance of Helicobacter pylori isolated from Korea. J Antim Chem 2001; 47: 459-461
24. Boyanova L, Mentis A, Gubina M, Rozynek E, Gosciniak G, Kalenic S, Goral V, Kupcinskas L, Kantarceken B, Aydin A, Archimandritis A, Dzierzanowska D, Vcev A, Ivanova K, Marina M, Mitov I, Petrov P, Ozden A, Popova M. The status of antimicrobial resistance of Helicobacter pylori in eastern Europe. Clin Microbiol Infect 2002; 8: 388-396
25. Forne M, Viver JM, Esteve M, Fernandez-Banares F, Lite J, Espinos JC, Quintana S, Salas A, Garau J. Randomize clinical trial comparing two one week triple therapy regimens for the eradication of Helicobacter pylori infection and duodenal ulcer healing. Am J Gastroenterol 1998; 93: 35-38
26. Kim HS, Lee DK, Kim KH, Jeong YS, Kim JW, Seo JI, Baik SK, Kwon SO, Cho MY. Comparison of the efficacy and safety of different formulations of omeprazole-based triple theapies in the treatment of Helicobacter pylori-positive peptic ulcer. J Gastroenterol 2001; 36: 96-102
27. Graham DY, Lew GM, Malaty HM, Evans DG, Evans DJ Jr, Klein PD, Alpert LC, Genta RM. Factors influencing eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102: 493-496
28. Kung NN, Sung JJ, Yuen NW, Ng PW, Wong KC, Chung EC, Lim BH, Choi CH, Li TH, Ma HC, Kwok SP. Anti-Helicobacter pylori Treatment in Bleeding Ulcers: Randomized Controlled Trial Comparing 2-day versus 7-Day bismuth Quadruple Therapy. Am J Gastroenterol 1997; 92: 438-441
29. Megraud F. Resistance of Helicobacter pylori to antibiotics: the main limitation of current proton-pump inhibitor triple therapy. Eur J Gastroenterol Hepatol 1999; 11: (Suppl 2): S35-37
30. Kamada T, Haruma K, Komoto K, Mihara M, Chen X, Yoshihara M, Sumii K, Kajiyama G, Tahara K, Kawamura YM. Effect of smoking and histological gastritis severity on the rate of H pylori eradication with omeprazole, amoxicillin, and clarithromycin. Helicobacter 1999; 4: 204-210
31. Russo A, Maconi G, Spinelli P, Felice GD, Eboli M, Andreola S, Ravagnani F, Settesoldi D, Ferrari D, Lombardo C, Bertario L. Effect of lifestyle,smoking,and diet on development of intestinal metaplasia in H pylori-positive subject. Am J Gastroenterol 2001; 96: 1402-1408
32. Huang JQ, Hunt RH. Review: Eradication of Helicobacter pylori. Problems and recommendations. J Gastroenterol Hepatol 1997; 12: 590-598
33. Raviglione MC, O'Brien RJ. Tuberculosis.in Fauci A.S.ed. Harrison's principles of internal medicine. 14th ed.Newyork:MCGrow-Hill Co 1998: 1004-1014
34. Madkour M. Brucellosis in Fauci A.S.ed. Harrison's principles of internal medicine. 14th ed. Newyork:MCGrow-Hill co 1998: 1004-1014
35. Bjorkholm B, Zhukhovitsky V, Lofman C, Hulten K, Enroth H, Block M, Rigo R, Falk P, Engstrand L. Helicobacter pylori entery into human gastric epithelial cells: Apotential determinant of virulence, persistence, and treatment failures. Helicobacter 2000; 5: 148-154